I'm LongbridgeAI, I can summarize articles.Morgans analyst Scott Power has maintained a Buy rating on Impedimed Limited (IPDQF) with a price target of A$0.02. Despite Power's average return of -4.2% and a 37.28% success rate, the overall analyst consensus for Impedimed Limited is a Strong Buy, with an average price target of A$0.03.
Morgans analyst Scott Power maintained a Buy rating on Impedimed Limited today and set a price target of A$0.02.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Power is an analyst with an average return of -4.2% and a 37.28% success rate. Power covers the Healthcare sector, focusing on stocks such as Tetratherix Limited, EBOS Group Limited, and Impedimed Limited.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Impedimed Limited with a A$0.03 average price target.